This single-center retrospective cohort study divided 176 adults with biopsy-proven primary glomerulonephritis (GN) between 2014 and 2021 into 4 groups based on cortical interstitial fibrosis (IF) percentage. The primary outcome was disease progression, defined as a ≥40% decline in estimated glomerular filtration rate (eGFR) and/or the need for dialysis. The secondary outcome was complete remission, defined as proteinuria <300 mg/24 hours. Baseline proteinuria and serum creatinine increased with greater IF severity, while eGFR decreased. Kaplan-Meier analysis showed a higher risk of progression in patients with severe IF. After adjusting for glomerulosclerosis, baseline eGFR, proteinuria, and treatments, IF severity remained an independent predictor of progression (HR 3.15). IF was not independently associated with achieving complete remission. Stratified analyses suggested a stronger association in immunoglobulin-A (IgA) nephropathy, while results for focal segmental glomerulosclerosis (FSGS) and membranous glomerulonephritis (MGN) were inconclusive due to limited statistical power. In summary, the severity of IF on diagnostic biopsy is a strong and independent prognostic factor for disease progression in primary glomerular diseases, supporting its routine standardized assessment to improve risk stratification and personalized patient management.

Purpose:Crescentic glomerulonephritis (GN) is a rapidly progressive kidney disease associated with a high risk of end-stage renal disease (ESRD). This study aimed to assess whether systemic inflammation and nutritional status, as measured by the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI) at diagnosis, can predict one-year renal survival in patients with crescentic GN. Methods:This retrospective study included 82 adult patients with biopsy-proven Type 1 or Type 3 crescentic GN. Baseline SII and PNI were calculated from pre-treatment blood samples. Clinical, laboratory, and histopathological data were collected. Patients were followed for 12 months and classified into two groups based on the development of ESRD. Results:The cohort (63.4% male) had a mean age of 53.65 ± 15.87 years; 26 patients (31.7%) progressed to ESRD. Multivariate analysis identified elevated SII [OR: 1.79; 95% CI: 1.22-18.81; p = 0.03], low PNI [OR: 0.92, 95% CI: 0.96-0.99; p = 0.03], hypoalbuminemia [OR: 0.36, 95% CI: 0.15-0.84; p = 0.02], reduced estimated glomerular filtration rate [OR: 0.93, 95% CI: 0.88-0.98; p = 0.009], anemia [OR: 0.37; 95% CI: 0.22-0.63; p < 0.001], higher crescent ratio [OR: 1.05, 95% CI: 1.02-1.09; p = 0.02], and plasmapheresis requirement [OR: 0.074, 95% CI: 0.016-0.349; p = 0.001] as independent predictors of ESRD. Receiver operating characteristic analysis determined cutoff values of 176.38 for SII (area under the curve [AUC]: 0.679, p = 0.01) and 31.88 for PNI (AUC: 0.650, p = 0.03). Glomerulosclerosis ratio and interstitial fibrosis/tubular atrophy were not independently associated with ESRD (p = 0.13 and p = 0.14, respectively). Conclusion:SII and PNI are independent but moderate predictors of one-year renal survival in crescentic GN. Incorporating these readily available biomarkers with histological evaluation may enhance risk stratification and help guide early, aggressive immunosuppressive therapy.

Aim: This study aimed to compare blood cadmium (Cd) levels between hemodialysis (HD) and peritoneal dialysis (PD) patients and healthy controls, and to evaluate the associations between Cd levels and inflammatory, oxidative, and nutritional markers. Material and Methods: Sixty-one dialysis patients (31 HD, 30 PD) and 15 healthy controls were included in this cross-sectional study. Whole-blood Cd was measured by atomic absorption spectrometry and corrected for hemoglobin (cCd). Serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), and advanced oxidation protein products (AOPP) were analyzed as indicators of inflammation and oxidative stress. Results: Both whole-blood Cd and cCd levels were significantly higher in both HD and PD patients compared with healthy controls (p=0.021 and p=0.001, respectively), while no statistically significant difference was observed between the two dialysis modalities. Correlation analyses demonstrated that Cd levels were positively correlated with inflammatory and oxidative stress markers, including IL-6 (rs=0.338, p=0.003), hs-CRP (rs=0.464, p=0.001), MDA (rs=0.464, p=0.001), and AOPP (rs=0.454, p<0.001). In contrast, cCd levels showed a significant negative correlation with serum albumin concentrations (rs=-0.454, p=0.001). Conclusion: Cd accumulation is markedly increased in dialysis patients regardless of treatment modality and is closely linked to systemic inflammation, oxidative damage, and reduced nutritional status. Environmental Cd exposure may represent an under-recognized contributor to adverse clinical outcomes in chronic kidney disease (CKD), and preventive strategies to minimize Cd burden may help improve prognosis in this population.

Purpose:Controlled Nutritional Status (CONUT) score is strongly associated with mortality in various patient groups. This study aimed to assess the CONUT score's ability to predict mortality in Hemodialysis (HD) patients. Patients and Methods:Data from 243 patients who started HD between 2012 and 2020 were analyzed retrospectively. Laboratory test results within the first month after dialysis initiation were recorded and CONUT scores were calculated. Results:Over a mean follow-up duration of 32.2 months, the association between early (within six months) and late mortality was assessed. During this period, 119 patients (48.8%) died. Non-survivors had higher CONUT scores. The optimal cut-off for the CONUT score was 5.5. Sensitivity and specificity for predicting mortality were 62.2% and 61.23%, respectively. The optimal cut-off for early mortality was 6.5. Sensitivity and specificity for predicting early mortality were 68% and 69.3%, respectively. The CONUT score demonstrated moderate predictive accuracy for mortality (AUC 0.665) and higher accuracy for early mortality (AUC 0.729), highlighting its clinical utility in risk stratification. Conclusion:CONUT score at the beginning of HD is a reliable tool in predicting overall mortality in these patients, but it is especially useful in predicting early mortality.

Background/aim:Acute methanol poisoning (MP) poses a significant public health challenge, with inflammation increasingly recognized as a key factor in its pathophysiology. Identifying accessible and reliable prognostic biomarkers could help enhance clinical outcomes. This study aimed to assess the prognostic value of the systemic immune-inflammation index (SII) and the pan-immune-inflammation value (PIV), measured upon emergency department admission, in predicting in-hospital mortality in patients with acute MP. Material and methods:This retrospective study included patients diagnosed with acute MP at two tertiary care centers in Ankara, Türkiye: University of Health Sciences Dışkapı Yıldırım Beyazıt Education and Research Hospital (1 January 2015 to 1 October 2022) and Etlik City Hospital (1 October 2022 to 11 March 2025). Demographic, clinical, and laboratory data, along with treatment details and outcomes (discharge or inhospital death), were systematically recorded. Results:A total of 76 patients were included, of whom 92.1% were male, with a mean age of 49.0 ± 12.4 years. During hospitalization, 48.6% (n = 37) died. Both SII and PIV values at admission were significantly higher in nonsurvivors (p < 0.001 for SII; p = 0.031 for PIV). In multivariate Cox regression analysis, higher SII (HR: 2.44; 95% CI: 1.05-5.67; p = 0.034) and PIV (HR: 2.08; 95% CI: 1.05-4.13; p = 0.030) were independently associated with increased risk of mortality. Receiver operating characteristic (ROC) analysis showed an AUC of 0.750 (95% CI: 0.649-0.865) for SII, with an optimal cutoff of 665.6 (sensitivity: 50%; specificity: 46%), and an AUC of 0.640 (95% CI: 0.519-0.769) for PIV, with an optimal cutoff of 512.5 (sensitivity: 53%; specificity: 47%). Conclusion:SII and PIV measured at hospital admission may have potential prognostic value in predicting inhospital mortality in patients with acute MP.

Background: Patients with chronic diseases such as chronic kidney disease (CKD) have been reported to have more adverse outcomes during the coronavirus disease 2019 (COVID-19) pandemic. There are insufficient data on the outcomes of patients with primary glomerular diseases (PGD) after COVID-19. Methods: We designed a national multicenter observational study that included adult patients with biopsy -proven PGD who survived COVID-19. A control group was created from the same centers, including PGD patients without COVID-19. The clinical and laboratory data of the patients at baseline, first, and third months after COVID-19 were recorded. Results: A total of 129 patients from 21 centers were included (COVID-19 group, n = 77). Baseline characteristics were almost similar except the ratio of active disease in the non-COVID-19 group was significantly higher than in the COVID-19 group. No patients died during the first and third months. Respiratory symptoms were significantly higher in the COVID-19 group than in the non-COVID-19 group in the first month (7.8% vs. 0%, P = .039). All other follow-up outcomes, including initiation of chronic kidney replacement therapy and initiation of new immunosuppressive treatment, and the laboratory data were not different between the groups in the first and third months. Conclusion: Primary glomerular disease patients in the post-COVID-19 period had more respiratory symptoms than non-COVID-19 PGD patients, but outcomes, including death and initiation of kidney replacement therapy, were not different in the first and third months post COVID-19.

Abstract Background and Aims Sodium-glucose cotransporter 2 (SGLT2) inhibitors have become widely used in recent years because of favorable outcomes on kidney function in people with diabetes mellitus and chronic kidney disease (CKD). The main effect of SGLT2 inhibitors is inhibiting sodium and glucose reabsorption, acting precisely in the early proximal tubule of the renal nephron. Although these drugs developed as glucose-lowering agents for their capability to induce glycosuria, cardiovascular outcome studies found that the reduction in kidney function was significantly delayed, and the incidence of severe decline in kidney function was reduced in patients taking SGLT2 inhibitors. Later on, these outcomes were confirmed by the results of the DAPA-CKD, EMPA-KIDNEY, and CREDENCE studies, which were specific outcome trials in patients with CKD. However, data about the use of SGLT2 inhibitors in patients with glomerulonephritis at routine clinical practice are still limited. The purpose of this study is to investigate the impact of SGLT2 inhibitors use in patients with glomerulonephritis. Method Patients diagnosed with biopsy-proven GN who continued their routine follow-up in Etlik City Hospital nephrology clinic were retrospectively examined. Patients with a steroid treatment history for GN were excluded from this study. We identified 29 patients who were treated with SGLT2 inhibitors for proteinuria. We analyzed the baseline characteristics, comorbidities, GN types, and laboratory parameters (baseline, sixth and twelfth months at the follow-up). Each patient was matched to the control with a similar baseline feature under conservative therapy (n = 29). Both patient groups were treated in line with the KDIGO glomerulonephritis guideline and were received RAAS blockers at the maximum tolerated dose. According to baseline levels, the reduction rate in proteinuria and eGFR of the sixth and twelfth months were calculated as percentages. The study was performed in accordance with the Declaration of Helsinki. The local ethical committee approved the study design. Results Our study involved 58 patients diagnosed with 32 (55%) IgA nephropathy, 16 (28%) with membranous nephropathy, and 10 (17%) with focal segmental glomerulosclerosis. In the treatment group, 23 (79%) patients used dapagliflozin, and 6 (21%) used empagliflozin as SGLT2 inhibitors. Baseline proteinuria levels at [1940 (1780-2700 mg/d) vs. 1890 (1670-2400 mg/d); p = 0.8], eGFRs [60 (44-82) vs. 64 (46-80) ml/min/1.73 m2; p = 0.8] and serum albumin levels (39.6 ± 0.3 vs. 39.1 ± 0.2; p = 0.4) were similar between both groups. The proteinuria reduction rate in the sixth month was 34% (27.3-40.5) for the treatment group and 12% (6.9-20.7) for the control group (<0.0001). Besides, the reduction rate was still higher in the treatment group at the 12th month [50.5% (39-52.6) vs. 26.3% (17.2-35.4); p ≤ 0.0001]. eGFR declining rate at 6th months and 12th months were lower in SGLT2 group than the control group [3.1% (0-6.2) vs. 8.6% (4.1-16.6); p = 0.004 and 0.8% (0-5) vs. 5.9% (3.3-15.2); 0.005, respectively] (Table 1). Proteinuria levels at 6th months were 1170 (970-1890) mg/d and 1730 (1180-2100) mg/d for treatment and control group, respectively. At 12th months, median proteinuria level of SGLT2 group was 940 (840-1480) mg/d and control group was 1250 (1120- 2040) mg/d (Fig. 1). Conclusion In this study with a well-matched control group, we found that SGLT2 inhibitors demonstrate efficacy in mitigating the decline in estimated GFR and reducing albuminuria in patients with GN. However, randomized-controlled trials are still required specific to patients with GN.

Abstract Background and Aim Renal involvement of systemic lupus erythematosus (SLE) is known as lupus nephritis (LN). The prognosis of lupus patients with LN is worse than those without kidney involvement. Renal survival can be improved in patients with lupus nephritis with appropriate and timely treatment. The aim of our study is to compare the clinical and pathological findings of patients diagnosed with LN in our clinic by renal biopsy, the results of the treatment applied in our center, and renal survival with the literature. Method The local ethical committee approved the study design (date: 04/10/2021; reference number: 121/07) and all procedures were conducted in accordance with the Declaration of Helsinki. Forty-four patients diagnosed with lupus nephritis between January 2012 and January 2021 in the Nephrology Department of Ankara Dıskapı Yıldırım Beyazıt Education and Research Hospital were enrolled in this study. Patient data were analyzed retrospectively. Exclusion criteria were as follows: 1) Patients under 18 years of age, 2) patients with follow-up of period less than 6 months and who did not attend regular follow-ups, 3) patients with connective tissue diseases other than SLE. Results The mean age of the study population was 36.0 ± 10.8, and the majority were female. All patients had proteinuria at diagnosis. Class IV LN was the most common (36.4%). Majority of the patients were in the proliferative LN group (65.9%). A significant difference was found between patients diagnosed with proliferative LN (n = 29) and non-proliferative LN (n = 15) in terms of high serum creatinine levels, low serum complement, presence of anti-dsDNA antibodies and active urinary sediment with proliferative LN (p = 0.021, p = 0.024, p = 0.008, p = 0.008). Treatment responses at 6 and 12 months are shown in Table 1. A significant difference was found between the patients who were in complete remission (n = 16) at 12 months and those who were not in remission (n = 27) in terms of low systolic blood pressure and the estimated glomerular filtration rate (eGFR) at the time of diagnosis (p = 0.008, p = 0.016). It was observed that most of the patients who were not in complete remission at 12 months were in the proliferative LN group (p = 0.024). There was no significant difference in the partial and complete remission rates at 6 and 12 months between the group receiving steroids + cyclophosphamide (n = 14) and the group receiving steroid + mycophenolate mofetil (MMF) (n = 15) in the initial treatment of proliferative LN (p>0.05). In the group taking MMF treatment (n = 15) had a shorter time to reach complete remission than the group taking cyclophosphamide treatment, and it was statistically significant (Table 2) (p = 0.048). It was found that end-stage renal disease (ESRD) developed in 9% of the patients and 2 patients died during followed up period. Recurrence was detected in 8 patients, and it was observed that more than half of the patients with relapse could not achieve complete remission at 12 months. Patients with relapse had higher systolic blood pressure and serum total cholesterol level at the time of diagnosis compared to patients without recurrence (p = 0.013, p = 0.045). In addition, patients with relapse were found to have a higher level of proteinuria at the time of diagnosis (p = 0.036). Conclusion Lupus nephritis remains an important source of morbidity and mortality for SLE patients. SLE patients should be regularly examined for renal involvement. About 10-20% of patients diagnosed with lupus nephritis develop ESRD. Early diagnosis of LN and initiating appropriate treatment when diagnosed without delay is important for renal and patient survival. Although there were some different results, most of the statistically significant data in our study were found to be compatible with the existing literature. However, these data need to be confirmed by studies with high patient participation.

Abstract Background and Aims The main purpose of this study is to determine the effect of dialysis on the prognosis (admission to intensive care unit, intubation requirement, length of hospitalization, mortality) of patients with COVID-19 receiving hemodialysis treatment in our clinics. Another aim of this study is to examine the effect of the need for hemodialysis on COVID-19 prognosis in order to contribute to the data of our country. Method Cross-sectional study of 104 patients with hemodialysis and were diagnosed COVID-19 were conducted. In this study, patients were divided into three groups: (i) those with chronic renal failure (CRF) and receiving routine hemodialysis; (ii) those with chronic kidney disease (CKD) but needing urgent hemodialysis; and (iii) those who did not have a known kidney disease but needed urgent hemodialysis because of acute kidney injury (AKI) . The study was performed in accordance with the Declaration of Helsinki. The local ethical committee approved the study design (date: 21.03.2022; reference number: 133/13). Results When we evaluated the demographic, clinical and laboratory factors in our study, it was found that the factors affecting mortality were lymphopenia, emergency HD treatment under the presence of CKD, an increase in AST more than 2 times, the need for mechanical ventilation and high d-dimer (Table 1). Conclusion This case demonstrates that AKI associated with cytokine storm and developing multi-organ dysfunction situation is directly linked to mortality, particularly in patients with severe clinical condition. When the biochemical data of the patients were analysed, it was discovered that AST increase, lymphopenia, and d-dimer rise were directly found associated with increase mortality. In light of these observations, the above-mentioned biochemical laboratory values of the patients can be closely monitored, as can the clinical course of COVID-19 and renal-related mortality.

Aim: In this study, we aimed to present demographic characteristics of the patients having undergone renal transplantation in our hospital between February 2017 and September 2020, to convey the experience of cadaver and living donor renal transplantation in our center, and to reveal the causes of allograft dysfunction in late posttransplant follow-ups. Material and Method:The study included 25 patients having undergone renal transplantation in our hospital and were followed up in the nephrology clinic between February 2017 and September 2020.Then, we retrospectively analyzed their demographic characteristics, clinical and laboratory findings, transplantation types, kidney donor characteristics, renal failure etiologies, pre-transplant dialysis modalities, post-transplant complications, rejection attacks, graft loss, and causes of mortalities. Results:The mean follow-up period of 25 renal transplant patients (17 males and 8 females with a mean age of 46.96±2.67 years) was 26.28±2.76months.While living transplantation was performed in 16 patients, the others received cadaveric renal transplants.Five patients underwent pre-emptive renal transplantation, and three were recruited for transplant for the second time.The underlying cause of chronic kidney disease was unknown in 24% of the patients (first), while vesicoureteral reflux (VUR) and diabetes were the primary causes of the disease in 16% (second).The most prevalent cause of temporary or permanent impairment in allograft functions was urinary tract infection with 42.8%.It was more common in female patients (25%) and patients with a diagnosis of VUR (20%). Conclusion:Overall, our findings documented that urinary system infections are common following renal transplantation, which brings adverse effects on allograft functions.VUR-led renal failure and female gender are among the factors that facilitate urinary system infection.

OBJECTIVES:The aim of this study was to investigate the characteristics of de novo malignancies arising in kidney transplant recipients followed in a tertiary hospital in Turkey and to examine the tumors in the head and neck region as a subgroup. MATERIALS AND METHODS:Data from kidney transplant recipients treated at our institution between January 2010 and July 2022 were retrospectively analyzed in this single-center study. Data regarding malignancies were noted according to the pathologists' reports. In situ malignancies and those arising after graft loss were not evaluated. RESULTS:The study population comprised 231 patients (165 men; 71.4%) with a median follow-up of 11 years (2853 patient-years). The recipients had a higher cancer risk than the general population (standardized incidence rate = 3.04; 95% CI, 1.82-4.26). Thirty de novo malignant tumors were detected in 24 patients (10.4%). The mean age at diagnosis of cancer was 54.88 ± 11.44 years. The median time from transplant to cancer diagnosis was 11.5 years (range, 7-18.8 y). Nonmelanoma skin cancers (56.7% of all tumors) were the most common malignancies. Twenty-two lesions (73.3%) that developed in 17 patients (7.4%) were localized to the head and neck region: 15 (68.2%) were cutaneous and 7 (31.8%) were noncutaneous. The median time from transplant to head and neck cancer diagnosis was 12 years (range, 7.5-17.5 y). Mortality rate was higher in cancer patients (10 [41.7%] vs 17 [8.2%]; P < 0.01). CONCLUSIONS:The incidence of de novo malignancy in kidney transplant recipients was relatively higher compared with previous data. Nonmelanoma skin cancers were the most common type. Three-quarters of all lesions were in the head and neck region, and two-thirds were of cutaneous origin.

Acute renal artery thromboembolism is a rare clinical condition, and the most common cause is atrial fibrillation. Its' clinical presentation is hypertension and hematuria, accompanied by sudden-onset severe abdominal pain. We aimed to present a case of acute renal allograft thromboembolism and to discuss the diagnostic and therapeutic challenges of this rare clinical entity. A 68-year-old male patient, who had a living kidney transplant 14 years ago, initially presented with a decrease in urine output, bloody urination, and flank pain lasting for 3 days. On physical examination, widespread tenderness was detected over the transplanted kidney and cardiac beats were arrhythmic. The electrocardiography revealed new-onset atrial fibrillation. In the transplanted kidney, Doppler ultrasound renal artery flow was not observed. Acute renal artery thromboembolism was seen in the renal artery angiography. The patient did not respond to catheter-based heparin and thrombolytic therapy and was accepted as end-stage renal disease. Although being a rare condition, acute renal infarction should be suspected in a renal transplant recipient with atrial fibrillation presenting with hematuria, acute onset abdominal pain, and acute renal failure.

BACKGROUND:The aim of this study is to analyze and compare the predictive values of the Geriatric Nutritional Risk Index (GNRI) and Creatinine Index (CI) in the short-term mortality of maintenance hemodialysis patients and to determine their best cut-offs. METHODS:A total of 169 adult hemodialysis patients were included in this retrospective, cross-sectional, and single-center study. The demographic, clinical, and laboratory data of the month in which the patients were included in the study were obtained from their medical files and computer records. All-cause death was the primary outcome of the study during a 12-month follow-up after baseline GNRI and CI calculations. RESULTS:The mean age of the study population was 57 ± 16 years (49.7% were women, 15% were diabetic). During the one-year observation period, 19 (11.24%) of the cases died (8 CV deaths). The optimal cut-off value for GNRI was determined as 104.2 by ROC analysis [AUC = 0.682 ± 0.06, (95% CI, 0.549-0.815), p = 0.01]. The low GNRI group had a higher risk for all-cause and CV mortality compared to the higher GNRI group (p = 0.02 for both in log-rank test). The optimal sex-specific cut-off was 12.18 mg/kg/day for men [AUC = 0.723 ± 0.07, (95% CI, 0.574-0.875), p = 0.03] and was 12.08 mg/kg/day for females [AUC = 0.649 ± 0.13, (95% CI, 0.384- 0.914), p = 0.01]. Patients with lower sex-specific CI values had higher all-cause and CV mortality (p = 0.001 and p = 0.009 in log-rank test, respectively). In multivariate cox models, both GNRI [HR = 4.904 (% 95 CI, 1.77-13.56), p = 0.002] and sex-specific CI [HR = 5.1 (95% CI, 1.38-18.9), p = 0.01] predicted all-cause mortality. The association of GNRI with CV was lost [HR = 2.6 (CI 95%, 0.54-13.455), p = 0.22], but low CI had a very strong association with CV mortality [HR = 11.48 (CI 95%, 1.25 -104), p = 0.03]. DISCUSSION:In hemodialysis patients, GNRI and CI have similar powers in predicting all-cause short-term mortality. The association of CI with all-cause death depends on gender. On the other hand, sex-specific CI predicts CV mortality better than GNRI.

Objective: Advanced age, need for dialysis and high creatinine values at the time of admission, anti-glomerular basement membrane antibody positivity, pulmonary hemorrhage, and fibrous crescents on pathology are known poor prognostic factors in rapidly progressive glomerulonephritis. Our study aimed to determine the clinical, laboratory, and pathological factors affecting the kidney prognosis in the progression to end-stage kidney failure disease in our rapidly progressive glomerulonephritis patients. Methods: This study was made with 52 patients diagnosed with type 1 and type 3 rapidly progressive glomerulonephritis. The study continued with 37 eligible patients. Results: The patients' mean age was 52.3 +/- 11.06 and 22 (59.4%) were male. In 6 patients (16.2%), anti-glomerular basement membrane positivity, in 11 patients (29.7%), cytoplasmic anti-neutrophilic cytoplasmic antibody positivity, and in 20 patients (54.1%), perinuclear anti-neutrophilic cytoplasmic antibody positivity was detected. Parathyroid hormone value was higher in the perinuclear anti-neutrophilic cytoplasmic antibody-positive group at the time of biopsy (P =.005). Serum sodium levels were lower at the biopsy time in the patient group with a crescent rate above 65% (P =.014). Patients with end-stage kidney failure disease were younger, and their serum sodium levels expressively were lower at the biopsy time (P =.006, P =.02 respectively). When the risk factors affecting end-stage kidney failure disease were examined in multivariate regression analysis, it was observed that while sodium and parathyroid hormone values were not risk factors at the time of biopsy, age (P =.048) and time until diagnosis were risk factors (P =.048). Conclusion: In our study, the risk factors affecting end-stage kidney failure disease progression in rapidly progressive glomerulonephritis patients were age and the time until diagnosis. Kidney biopsy is essential for the kidney prognosis for rapid diagnosis, especially in young patients with suspected rapidly progressive glomerulonephritis.

Aim: This study aims to determine the frequency of kidney diseases based on histological diagnosis and to evaluate the relationship between clinical and histopathological findings in patients undergoing percutaneous kidney biopsy for various indications. Material and Method: In this cross-sectional study, demographic, anthropometric and laboratory data of the patients were obtained retrospectively from medical files and computer records. Biopsy indications and histopathological diagnoses (primary glomerular diseases, secondary glomerular diseases, tubulointerstitial diseases and other causes) of the patients were examined. Results: Of 103 patients, 57 (55.3%) were male and 46 (44.7%) were female. The mean age of the patients was 44.67±15.29 years. The most common biopsy indication was hematuria+proteinuria+renal dysfunction (n=28, 27.2%). The most common pathology in histopathological diagnoses was primary glomerular diseases (56.3%), the most common diagnosis was IgAN (n=16, 15.5%). Tubulointerstitial diseases were seen more frequently in the 60 years and older group. (n=4, 25%). The most common cause of secondary glomerulonephritis was AA amyloidosis. The number of tubular disorders increased with advanced age. Conclusion: In our center, renal biopsy was performed most frequently with the combination of proteinuria, hematuria, and renal dysfunction. The most common histopathological result was primary glomerulonephritis, in which IgAN took the first place.

Primary hyperaldosteronism (PH) is the excessive and uncontrolled production of aldosterone from the adrenal glands. Until now, the disease was frequently discussed among the endocrine causes of secondary hypertension, and patients with particularly resistant hypertension were included in the risk group. However, the data that emerged over the years have changed this perspective. Currently, the incidence of PH among hypertensive patients is more than 20% and it is clear that it affects a much larger population than previously thought. We consider that PH is an important public health problem and should be considered by all physicians dealing with the hypertensive population. In this article, we aim to create a practical approach to the diagnosis of PH from our clinical viewpoint and in the light of the contemporary literature.